<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SHIMURA, YUSUKE</style></author><author><style face="normal" font="default" size="100%">SUGA, YUKIO</style></author><author><style face="normal" font="default" size="100%">ITAI, SHINGO</style></author><author><style face="normal" font="default" size="100%">IWAMOTO, HIROAKI</style></author><author><style face="normal" font="default" size="100%">TAKEZAWA, YUTA</style></author><author><style face="normal" font="default" size="100%">YAEGASHI, HIROSHI</style></author><author><style face="normal" font="default" size="100%">IZUMI, KOUJI</style></author><author><style face="normal" font="default" size="100%">SHIMADA, TSUTOMU</style></author><author><style face="normal" font="default" size="100%">SAI, YOSHIMICHI</style></author><author><style face="normal" font="default" size="100%">MATSUSHITA, RYO</style></author><author><style face="normal" font="default" size="100%">MIZOKAMI, ATSUSHI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4291-4297</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14431</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">8</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The tolerability of 2-weekly docetaxel at 25-35 mg/m2 for castration-resistant prostate cancer (CRPC) has not been fully evaluated. The aim of this study was to evaluate its tolerability compared to 3-weekly docetaxel at 60-75 mg/m2 in patients with CRPC. Patients and Methods: In this retrospective study, data were compared with respect to efficacy and safety between 2-weekly and 3-weekly docetaxel regimens in patients with CRPC. Results: Time to treatment failure and prostate-specific antigen (PSA) response rate did not differ significantly between the two regimens. Compared to 3-weekly administration, incidence of severe leukopenia and febrile neutropenia was significantly lower (p&lt;0.05), and relative dose intensity was significantly higher (p&lt;0.05) for the 2-weekly schedule. Docetaxel dosage and PSA response were identified as independent risk factors for severe leukopenia. Conclusion: Two-weekly treatment seems better tolerated than three-weekly treatment in Japanese patients with CRPC.</style></abstract></record></records></xml>